Skip to content

Study · Systematic review · n = 3,288 · 2024

6 results

Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.

Müllertz ALO, Sandsdal RM, Jensen SBK, Torekov SS

Obesity reviews : an official journal of the International Association for the Study of Obesity11 Mar 2024Cited by 34 (Europe PMC)

PMID38463003 (opens in a new tab)DOI10.1111/obr.13717 (opens in a new tab)PepBankPUB-38463003
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In people with obesity without diabetes, semaglutide 2.4 mg reduced body weight versus placebo.

    In plain wordsIn people with obesity and no diabetes, semaglutide led to more weight loss than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreasePlacebo-subtracted body weight change
    Study

    n = 3,288

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Measurements

    Placebo-subtracted difference in body weight
    −12.9%
    semaglutide

    Source sentences

    Summary
    -12.9% (95% CI, -14.7 to -11.1) for semaglutide and -19.2% (95% CI, -22.2 to -16.2) for tirzepatide.
    3 context sentences
    Summary · context
    This study assessed the efficacy and safety of the incretin-based obesity treatments, once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg, in people with obesity without diabetes.
    Summary · context
    Of the 744 records identified, seven randomized controlled trials (n = 5140) were included.
    Summary · context
    Five studies (n = 3288) investigated semaglutide and two studies (n = 1852) investigated tirzepatide.
  2. 02HumanSystematic reviewEfficacy outcome

    In people with obesity without diabetes, semaglutide 2.4 mg reduced waist circumference versus placebo.

    In plain wordsIn people with obesity and no diabetes, semaglutide shrank waist size more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreasePlacebo-subtracted waist circumference change
    Study

    n = 3,288

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Measurements

    Placebo-subtracted difference in waist circumference
    −9.7 cm
    semaglutide

    Source sentences

    Summary
    -9.7 cm (95% CI, -10.8 to -8.5) for semaglutide and -14.6 cm (95% CI, -15.8 to -13.4) for tirzepatide.
    3 context sentences
    Summary · context
    This study assessed the efficacy and safety of the incretin-based obesity treatments, once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg, in people with obesity without diabetes.
    Summary · context
    Of the 744 records identified, seven randomized controlled trials (n = 5140) were included.
    Summary · context
    Five studies (n = 3288) investigated semaglutide and two studies (n = 1852) investigated tirzepatide.
  3. 03HumanSystematic reviewSafety outcome

    In people with obesity without diabetes, adverse events with semaglutide 2.4 mg were mostly mild to moderate and gastrointestinal, and more frequent during dose titration.

    In plain wordsIn people with obesity and no diabetes, semaglutide side effects were mostly mild to moderate stomach and gut problems, more often during dose increases.

    Peptide
    Semaglutide
    Outcome
    Not applicableAdverse events (mostly gastrointestinal)
    Study

    n = 3,288

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The adverse events related to semaglutide and tirzepatide were primarily of mild-to-moderate severity and mostly gastrointestinal, which was more frequent during the dose-titration period and leveled off during the treatment period.
    3 context sentences
    Summary · context
    This study assessed the efficacy and safety of the incretin-based obesity treatments, once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg, in people with obesity without diabetes.
    Summary · context
    Of the 744 records identified, seven randomized controlled trials (n = 5140) were included.
    Summary · context
    Five studies (n = 3288) investigated semaglutide and two studies (n = 1852) investigated tirzepatide.
  4. 04HumanSystematic reviewEfficacy outcome

    In people with obesity without diabetes, tirzepatide 10 or 15 mg reduced body weight versus placebo.

    In plain wordsIn people with obesity and no diabetes, tirzepatide led to more weight loss than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreasePlacebo-subtracted body weight change
    Study

    n = 1,852

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 or 15 mg once weekly · subcutaneousAs given in this study (human).

    Measurements

    Placebo-subtracted difference in body weight
    −19.2%
    tirzepatide

    Source sentences

    Summary
    -12.9% (95% CI, -14.7 to -11.1) for semaglutide and -19.2% (95% CI, -22.2 to -16.2) for tirzepatide.
    3 context sentences
    Summary · context
    This study assessed the efficacy and safety of the incretin-based obesity treatments, once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg, in people with obesity without diabetes.
    Summary · context
    Of the 744 records identified, seven randomized controlled trials (n = 5140) were included.
    Summary · context
    Five studies (n = 3288) investigated semaglutide and two studies (n = 1852) investigated tirzepatide.
  5. 05HumanSystematic reviewEfficacy outcome

    In people with obesity without diabetes, tirzepatide 10 or 15 mg reduced waist circumference versus placebo.

    In plain wordsIn people with obesity and no diabetes, tirzepatide shrank waist size more than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreasePlacebo-subtracted waist circumference change
    Study

    n = 1,852

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 or 15 mg once weekly · subcutaneousAs given in this study (human).

    Measurements

    Placebo-subtracted difference in waist circumference
    −14.6 cm
    tirzepatide

    Source sentences

    Summary
    -14.6 cm (95% CI, -15.8 to -13.4) for tirzepatide.
    3 context sentences
    Summary · context
    This study assessed the efficacy and safety of the incretin-based obesity treatments, once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg, in people with obesity without diabetes.
    Summary · context
    Of the 744 records identified, seven randomized controlled trials (n = 5140) were included.
    Summary · context
    Five studies (n = 3288) investigated semaglutide and two studies (n = 1852) investigated tirzepatide.
  6. 06HumanSystematic reviewSafety outcome

    In people with obesity without diabetes, adverse events with tirzepatide 10 or 15 mg were mostly mild to moderate and gastrointestinal, and more frequent during dose titration.

    In plain wordsIn people with obesity and no diabetes, tirzepatide side effects were mostly mild to moderate stomach and gut problems, more often during dose increases.

    Peptide
    Tirzepatide
    Outcome
    Not applicableAdverse events (mostly gastrointestinal)
    Study

    n = 1,852

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    10 or 15 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The adverse events related to semaglutide and tirzepatide were primarily of mild-to-moderate severity and mostly gastrointestinal, which was more frequent during the dose-titration period and leveled off during the treatment period.
    3 context sentences
    Summary · context
    This study assessed the efficacy and safety of the incretin-based obesity treatments, once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg, in people with obesity without diabetes.
    Summary · context
    Of the 744 records identified, seven randomized controlled trials (n = 5140) were included.
    Summary · context
    Five studies (n = 3288) investigated semaglutide and two studies (n = 1852) investigated tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.